Literature DB >> 33926462

Systematic analysis of direct antiglobulin test results in post-artesunate delayed haemolysis.

Tommaso Ascoli Bartoli1, Luciana Lepore1, Alessandra D'Abramo2, Giovanna Adamo1, Angela Corpolongo1, Laura Scorzolini1, Maria Letizia Giancola1, Nazario Bevilacqua1, Claudia Palazzolo1, Andrea Mariano1, Giuseppe Ippolito1, Pierre Buffet3,4, Emanuele Nicastri1.   

Abstract

BACKGROUND: Post-artesunate delayed haemolysis (PADH) is common after severe malaria episodes. PADH is related to the "pitting" phenomenon and the synchronous delayed clearance of once-infected erythrocytes, initially spared during treatment. However, direct antiglobulin test (DAT) positivity has been reported in several PADH cases, suggesting a contribution of immune-mediated erythrocyte clearance. The aim of the present study was to compare clinical features of cases presenting a positive or negative DAT.
METHODS: Articles reporting clinical data of patients diagnosed with PADH, for whom DAT had been performed, were collected from PubMed database. Data retrieved from single patients were extracted and univariate analysis was performed in order to identify features potentially related to DAT results and steroids use.
RESULTS: Twenty-two studies reporting 39 PADH cases were included: median baseline parasitaemia was 20.8% (IQR: 11.2-30) and DAT was positive in 17 cases (45.5%). Compared to DAT-negative individuals, DAT-positive patients were older (49.5 vs 31; p = 0.01), had a higher baseline parasitaemia (27% vs 17%; p = 0.03) and were more commonly treated with systemic steroids (11 vs 3 patients, p = 0.002). Depth and kinetics of delayed anaemia were not associated with DAT positivity.
CONCLUSIONS: In this case series, almost half of the patients affected by PADH had a positive DAT. An obvious difference between the clinical courses of patients presenting with a positive or negative DAT was lacking. This observation suggests that DAT result may not be indicative of a pathogenic role of anti-erythrocytes antibodies in patients affected by PADH, but it may be rather a marker of immune activation.

Entities:  

Keywords:  Artemisinins; Artesunate; Coombs test; Drug-related side effects and adverse reactions; Hemolytic anemia; Malaria

Year:  2021        PMID: 33926462     DOI: 10.1186/s12936-021-03735-w

Source DB:  PubMed          Journal:  Malar J        ISSN: 1475-2875            Impact factor:   2.979


  52 in total

Review 1.  The assessment of antimalarial drug efficacy.

Authors:  Nicholas J White
Journal:  Trends Parasitol       Date:  2002-10

2.  Case definition: postartemisinin delayed hemolysis.

Authors:  Paul M Arguin
Journal:  Blood       Date:  2014-07-10       Impact factor: 22.113

3.  Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.

Authors:  Arjen Dondorp; François Nosten; Kasia Stepniewska; Nick Day; Nick White
Journal:  Lancet       Date:  2005 Aug 27-Sep 2       Impact factor: 79.321

4.  Haemolytic anaemia after oral artemether-lumefantrine treatment in a patient affected by severe imported falciparum malaria.

Authors:  P De Nardo; A Oliva; M L Giancola; P Ghirga; P Mencarini; M Bibas; E Nicastri; A Antinori; A Corpolongo
Journal:  Infection       Date:  2013-04-04       Impact factor: 3.553

5.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.

Authors:  Arjen M Dondorp; Caterina I Fanello; Ilse C E Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A Mokuolu; Olanrewaju T Adedoyin; Wahab B R Johnson; Antoinette K Tshefu; Marie A Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E Peto; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White
Journal:  Lancet       Date:  2010-11-07       Impact factor: 79.321

6.  Intravenous artesunate for severe malaria in travelers, Europe.

Authors:  Thomas Zoller; Thomas Junghanss; Annette Kapaun; Ida Gjorup; Joachim Richter; Mats Hugo-Persson; Kristine Mørch; Behruz Foroutan; Norbert Suttorp; Salih Yürek; Holger Flick
Journal:  Emerg Infect Dis       Date:  2011-05       Impact factor: 6.883

7.  Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium.

Authors:  Annemarie R Kreeftmeijer-Vegter; Perry J van Genderen; Leo G Visser; Wouter F W Bierman; Jan Clerinx; Cees K W van Veldhuizen; Peter J de Vries
Journal:  Malar J       Date:  2012-03-31       Impact factor: 2.979

8.  Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013.

Authors:  Stéphane Jauréguiberry; Marc Thellier; Papa Alioune Ndour; Flavie Ader; Camille Roussel; Romain Sonneville; Julien Mayaux; Sophie Matheron; Adela Angoulvant; Benjamin Wyplosz; Christophe Rapp; Thierry Pistone; Bénédicte Lebrun-Vignes; Eric Kendjo; Martin Danis; Sandrine Houzé; François Bricaire; Dominique Mazier; Pierre Buffet; Eric Caumes
Journal:  Emerg Infect Dis       Date:  2015-05       Impact factor: 6.883

9.  Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis.

Authors:  Thierry Rolling; Dominic Wichmann; Stefan Schmiedel; Gerd D Burchard; Stefan Kluge; Jakob P Cramer
Journal:  Malar J       Date:  2013-07-15       Impact factor: 2.979

10.  Severe malaria in Europe: an 8-year multi-centre observational study.

Authors:  Florian Kurth; Michel Develoux; Matthieu Mechain; Denis Malvy; Jan Clerinx; Spinello Antinori; Ida E Gjørup; Joaquím Gascon; Kristine Mørch; Emanuele Nicastri; Michael Ramharter; Alessandro Bartoloni; Leo Visser; Thierry Rolling; Philipp Zanger; Guido Calleri; Joaquín Salas-Coronas; Henrik Nielsen; Gudrun Just-Nübling; Andreas Neumayr; Anna Hachfeld; Matthias L Schmid; Pietro Antonini; Tilman Lingscheid; Peter Kern; Annette Kapaun; José Saraiva da Cunha; Peter Pongratz; Antoni Soriano-Arandes; Mirjam Schunk; Norbert Suttorp; Christoph Hatz; Thomas Zoller
Journal:  Malar J       Date:  2017-01-31       Impact factor: 2.979

View more
  2 in total

1.  Case Report: Autoimmune Hemolysis Anemia After Dihydroartemisinin and Piperaquine for Uncomplicated Plasmodium falciparum Malaria.

Authors:  Marion Louvois; Loïc Simon; Christelle Pomares; Pierre-Yves Jeandel; Elisa Demonchy; Michel Carles; Pascal Delaunay; Johan Courjon
Journal:  Front Med (Lausanne)       Date:  2022-01-17

2.  Treatment for Severe Malaria: Post-Artesunate Delayed Haemolysis and Neutropenia.

Authors:  Mariangela Martino; Cecilia Liberati; Benedetta Bua; Elisa Barbieri; Paola Costenaro; Costanza Di Chiara; Carlo Giaquinto; Ettore De Canale; Osvalda Rampon; Daniele Donà
Journal:  Healthcare (Basel)       Date:  2022-02-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.